Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glesorasib, Ivonescimab, and Chemotherapy in Resectable KRAS G12C-Mutant NSCLC
NCT07472478Phase 2Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of garsorasib in non-small cell lung cancer (NSCLC), sponsored by Guangdong Provincial People's Hospital. Started Mar 2026; status: recruiting.
02
Drugs
garsorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07472478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07472478.